Member (English)

Staff

HAGIWARA Yasuhiro

Research Associate

Department of Biostatistics, Division of Health Sciences and Nursing

hagiwara [at] epistat.m.u-tokyo.ac.jp

Research

My methodological interests include (1) causal inference in clinical and epidemiological researches and (2) statistical methods in health economics and outcomes researches (HEOR). Now I'm working in the following research projects.

-Causal inference in clinical and epidemiologic researches
1. Methods for estimating the effects of time-varying treatments on a survival outcome
(Hagiwara et al. Biometrics. 2020. Hagiwara et al. Biometrics. 2021.)
2. Methods using Identity and log link functions for a binary outcome
(Hagiwara et al. Am J Epidemiol. 2018. Fuyama et al. Emerg Themes Epidemiol. 2021.)

-Statistical methods in HEOR
1. Statistical methods for mapping a non-preference-based measure onto a health utility measure
(Hagiwara et al. Value Health. 2020. Hagiwara et al. Health Qual Life Outcomes. 2020. Hagiwara et al. Value Health. 2023.)
2. Statistical methods for value-based pricing in health technology assessment
(Hagiwara et al. Med Decis Making. 2022.)

As a biostatistician, I have participated in various clinical studies especially in oncology. In particular, I have much experience on health-related quality of life studies (Hagiwara et al. ESMO Open. 2017. Hagiwara et al. Eur J Cancer. 2018. Hagiwara et al. Pharmacoeconomics. 2018. Hagiwara et al. Breast Cancer Res Treat. 2021. Izumi et al. Health Qual Life Outcomes. 2023.).

Career

2014.3 BSc (health science) in The University of Tokyo
2016.3 MPH in The University of Tokyo
2019.3 PhD (health science) in The University of Tokyo
2019.4 Assistant professor at Department of Biostatistics, The University of Tokyo

Activity

Membership:
-Member, International Biometric Society
-Member, The Biometric Society of Japan
-Member, International Society of Pharmacoeconomics and Outcomes Research
-Member, Japanese Society for Quality of Life and Patient-Reported Outcomes Research

Awards:
-ISPOR (International Society for Pharmacoeconomics and Outcomes Research) Asia Pacific 2018 Best Student Poster Research Presentation
-Encouragement Award, The Biometric Society of Japan, 2021

Paper

  1. Takeuchi Y, Hagiwara Y, Komukai S, Matsuyama Y. Estimation of the causal effects of time-varying treatments in nested case-control studies using marginal structural Cox models. Biometrics. 2024;80:ujae005.
  2. Taira N, Kikawa Y, Iwamoto T, Miyoshi Y, Hara K, Yoshitomi S, Hikino H, Takahashi H, Takabatake D, Kubo S, Ikeda M, Doihara H, Shien T, Okuyama H, Tanabe Y, Hara F, Yamanouchi K, Hagiwara Y, Sawaki M. Pilot trial of an electronic patient-reported outcome monitoring system in patients with metastatic breast cancer undergoing chemotherapy. Breast Cancer. 2024. doi: 10.1007/s12282-023-01537-3. Online ahead of print.
  3. Takada M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Ohno S, Ishiguro H, Kanbayashi C, Miyamoto T, Hagiwara Y, Toi M. A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer. Breast Cancer Res Treat. 2023. doi: 10.1007/s10549-023-07099-4. Online ahead of print.
  4. Fukuhara H, Hagiwara Y, Oba K, Inoue K. Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (3rd report): cost impact of transurethral resection of bladder tumor in Japan. Photodiagnosis Photodyn Ther. 2023;103758. doi: 10.1016/j.pdpdt.2023.103758.
  5. Hagiwara Y. Using a sample size calculation framework for clinical prediction models when developing and selecting mapping algorithms based on linear regression. Med Decis Making. 2023. doi: 10.1177/0272989X231188134. Online ahead of print.
  6. Suzuki Y, Iwamoto T, Uno M, Hatono M, Kajiwara Y, Takahashi Y, Kochi M, Shien T, Kikawa Y, Uemura Y, Hagiwara Y, Yamamoto S, Taira N, Doihara H, Toyooka S. Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer. Breast Cancer. 2023. doi: 10.1007/s12282-023-01480-3. Online ahead of print.
  7. Izumi S, Hagiwara Y, Matsuyama Y, Shiroiwa T, Taira N, Kawahara T, Konomura K, Noto S, Fukuda T, Shimozuma K. Impacts of the preceding cancer-specific health-related quality of life instruments on the responses to the subsequent EQ-5D-5L. Health Qual Life Outcomes. 2023;21:3.
  8. Okada A, Yamada G, Kimura T, Hagiwara Y, Yamaguchi S, Kurakawa KI, Nangaku M, Yamauchi T, Matsuyama Y, Kadowaki T. Diagnostic ability using fatty liver and metabolic markers for metabolic-associated fatty liver disease stratified by metabolic/glycemic abnormalities. J Diabetes Investig. 2022. https://doi.org/10.1111/jdi.13966 Online ahead of print.
  9. Matsumoto H, Hagiwara Y, Yamamoto-Mitani N, Igarashi A. A randomized control trial for ReDeSign: A dementia-friendly mobile microlearning training for store workers in Japan. Gerontologist. 2022 Dec 12;gnac182. doi: 10.1093/geront/gnac182. Online ahead of print.
  10. Kikawa Y, Hagiwara Y, Fujisawa T, Araki K, Iwamoto T, Sangai T, Shien T, Takao S, Nishimura R, Takahashi M, Toyama T, Aihara T, Mukai H, Taira N. Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy. PLoS One. 2022;17:e0278344.
  11. Hagiwara Y, Shiroiwa T, Taira N, Kawahara T, Konomura K, Noto S, Fukuda T, Shimozuma K. Gradient boosted tree approaches for mapping European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 onto 5-level version of EQ-5D index for patients with cancer. Value Health. 2022. doi: 10.1016/j.jval.2022.07.020. Online ahead of print.
  12. Fujita S, Hagiwara A, Takei N, Fukunaga I, Hagiwara Y, Ogawa T, Hatano T, Rettmann D, Banerjee S, Hwang K, Amemiya S, Kamagata K, Hattori N, Abe O, Aoki S. Rigid real-time prospective motion-corrected three-dimensional multiparametric mapping of the human brain. Neuroimage. 2022;119176. doi: 10.1016/j.neuroimage.2022.119176. Online ahead of print.
  13. Fujita S, Cencini M, Buonincontri G, Takei N, Schulte RF, Fukunaga I, Uchida W, Hagiwara A, Kamagata K, Hagiwara Y, Matsuyama Y, Abe O, Tosetti M, Aoki S. Simultaneous Relaxometry and Morphometry of Human Brain Structures with Three-dimensional Magnetic Resonance Fingerprinting: A Multicenter, Multiplatform, Multi-field-strength Study. Cereb Cortex. 2022. doi: 10.1093/cercor/bhab259. Online ahead of print.
  14. Takumoto Y, Shiroiwa T, Shimozuma K, Iwata H, Takahashi M, Baba S, Kobayashi K, Hagiwara Y, Kawahara T, Uemura Y, Mukai H, Taira N, Sawaki M. Cost-effectiveness of trastuzumab with or without chemotherapy as adjuvant therapy in HER2-positive elderly breast cancer patients: a randomized, open-label clinical trial, the RESPECT trial. Clin Drug Investig. 2022. doi: 10.1007/s40261-022-01124-y. Online ahead of print.
  15. Hagiwara Y, Shiroiwa T. Estimating Value-Based Price and Quantifying Uncertainty Around It in Health Technology Assessment: Frequentist and Bayesian Approaches. Med Decis Making. 2022 Feb 17. doi: 10.1177/0272989X221079554. Online ahead of print.
  16. Matsumoto H, Igarashi A, Hagiwara Y, Yamamoto-Mitani N. Relational Design for Dementia and Job Significance (ReDeSign): Study protocol for a randomized controlled trial of an online dementia training for retail workers. Contemp Clin Trials Commun. 2022;26:100896.
  17. Ishimaru M, Ono S, Morita K, Matsui H, Hagiwara Y, Yasunaga H. Prevalence, incidence rate and risk factors of medication-related osteonecrosis of the jaw (MRONJ) in patients with osteoporosis and cancer: a nationwide population-based study in Japan. J Oral Maxillofac Surg. 2021;S0278-2391(21)01511-1. doi: 10.1016/j.joms.2021.12.007. Online ahead of print.
  18. Kawahara T, Taira N, Shiroiwa T, Hagiwara Y, Fukuda T, Uemura Y, Mukai H. Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: results from a randomized clinical trial. Qual Life Res. 2022 Jan 4. doi: 10.1007/s11136-021-03074-y. Online ahead of print.
  19. Fuyama K, Hagiwara Y, Matsuyama Y. A simulation study of regression approaches for estimating risk ratios in the presence of multiple confounders. Emerg Themes Epidemiol. 2021;18:18.
  20. Takeuchi Y, Ogawa M, Hagiwara Y, Matsuyama Y. Non-parametric approach for frequentist multiple imputation in survival analysis with missing covariates. Stat Methods Med Res. 2021; 30(7): 1691-1707.
  21. Hagiwara Y, Sawaki M, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Takahashi M, Saito T, Baba S, Kobayashi K, Mukai H, Taira N. Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial. Breast Cancer Res Treat. 2021. https://doi.org/10.1007/s10549-021-06253-0
  22. Shiroiwa T, Hagiwara Y, Taira N, Kawahara T, Konomura K, Iwamoto T, Noto S, Fukuda T, Shimozuma K. Randomized controlled trial of paper-based at a hospital versus continual electronic patient-Reported outcomes at home for metastatic cancer patients: does electronic measurement at home detect patients' health status in greater detail? Med Decis Making. 2021. doi:10.1177/0272989X211010171.
  23. Kawaguchi Y, Hasegawa K, Hagiwara Y, De Bellis M, Famularo S, Panettieri E, Matsuyama Y, Tateishi R, Ichikawa T, Kokudo T, Izumi N, Kubo S, Sakamoto M, Shiina S, Takayama T, Nakashima O, Murakami T, Vauthey JN, Giuliante F, De Carlis L, Romano F, Ruzzenente A, Guglielmi A, Kudo M, Kokudo N. Effect of diameter and number of hepatocellular carcinomas on survival after resection, trans-arterial chemoembolization, and ablation. Am J Gastroenterol. 2021. doi: 10.14309/ajg.0000000000001256.
  24. Hirose N, Morita K, Jo T, Hagiwara Y, Matsui H, Fushimi K, Yasunaga H. Differences in disease severity and in-hospital mortality in patients hospitalised for pneumonia with and without intellectual disabilities: A matched-pair retrospective cohort study using nationwide in-patient database. J Intellect Dev Disabil. Online ahead of print.
  25. Takeuchi Y, Kumamaru H, Hagiwara Y, Matsui H, Yasunaga H, Miyata H, Matsuyama Y. Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database. Diabetes Obes Metab. 2021; 23(6): 1379-1388.
  26. Hagiwara Y, Shiroiwa T, Taira N, Kawahara T, Konomura K, Noto S, Fukuda T, Shimozuma K. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer. Health Qual Life Outcomes. 2020;18:306.
  27. Yamada G, Hagiwara Y, Kimura T, Takeuchi Y, Oba K, Masuda K, Matsuyama Y. Impact of body weight gain on the incidence of non-alcoholic fatty liver disease in non-obese Japanese individuals. Am J Gastroenterol. 2021; 116(4): 733-740.
  28. Hagiwara Y, Kawahara T, Shiroiwa T. What is a valid mapping algorithm in cost-utility analyses? A response from a missing data perspective. Value Health. 2020;23:1218–1224.
  29. Hagiwara Y, Shinozaki T, Mukai H, Matsuyama Y. Sensitivity analysis for subsequent treatments in confirmatory oncology clinical trials: a two-stage stochastic dynamic treatment regime approach. Biometrics. 2020. doi: 10.1111/biom.13296. Online ahead of print.
  30. Hagiwara Y, Shinozaki T, Matsuyama Y. G‐estimation of structural nested restricted mean time lost models to estimate effects of time‐varying treatments on a failure time outcome. Biometrics. 2020;76:799–810.
  31. Yoshida T, Uchino S, Sasabuchi Y, Hagiwara Y, the AFTER-ICU study group. Prognostic impact of sustained new-onset atrial fibrillation in critically ill patients. Intensive Care Med. 2020;46:27–35.
  32. Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Ann Oncol. 2019;30:259-265.
  33. Ishimaru M, Matsui H, Ono S, Hagiwara Y, Morita K, Yasunaga H. Preoperative oral care and effect on postoperative complications after major cancer surgery. Br J Surg. 2018;105:1688-1696.
  34. Hagiwara Y, Fukuda M, Matsuyama Y. The number of events per confounder for valid estimation of risk difference using modified least-squares regression. Am J Epidemiol. 2018;187:2481-2490.
  35. Hagiwara Y, Ohashi Y, Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: results from a randomized phase III trial (JASPAC 01). Eur J Cancer. 2018;93:79-88.
  36. Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N, Liver Cancer Study Group of Japan. Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analyzed with propensity score weighting. Liver Int. 2018;38:484-493.
  37. Kawahara T, Shimozuma K, Shiroiwa T, Hagiwara Y, Uemura Y, Watanabe T, Taira N, Fukuda T, Ohashi Y, Mukai H. Patient-reported outcome results from the open-label randomized phase III SELECT BC trial evaluating first-line S-1 therapy for metastatic breast cancer. Oncology. 2018;94:107-115
  38. Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Kawahara T, Ohsumi S, Hozumi Y, Sagara Y, Ohashi Y, Mukai H. Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial. BMC Cancer. 2017;17:773.
  39. Hagiwara Y, Shiroiwa T, Shimozuma K, Kawahara T, Uemura Y, Watanabe T, Taira N, Fukuda T, Ohashi Y, Mukai H. Impact of adverse events on health utility and health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer: results from the SELECT BC study. Pharmacoeconomics. 2018;36:215-223.
  40. Mukai H, Hagiwara Y, Imi K, Isaka H, Watanabe K, Matsuyama Y for the SELECT BC Study Group. The impact of treatment preferences in second-line chemotherapy on the prognosis of HER2-negative metastatic breast cancer. Oncology. 2017;93:315-322.
  41. Shinozaki T, Hagiwara Y, Matsuyama Y. Re. Biases in randomized trials: a conversation between trialists and epidemiologists (Letter). Epidemiology. 2017; 28(4): e40-e41.
  42. Hagiwara Y, Ohashi Y, Okusaka T, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Cheng AL, Kihara K, Sato A, Tanaka M. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. ESMO Open. 2017;2:e000151.
  43. Yamaue H, Shimizu A, Hagiwara Y, Sho M, Yanagimoto H, Nakamori S, Ueno H, Ishii H, Kitano M, Sugimori K, Maguchi H, Ohkawa S, Imaoka H, Hashimoto D, Ueda K, Nebiki H, Nagakawa T, Isayama H, Yokota I, Ohashi Y, Shirasaka T. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer. Cancer Chemother Pharmacol. 2017;79:813-823.
  44. Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Ohashi Y, Mukai H. Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial. Qual Life Res. 2017;26:445-453.

Conference

  1. Takeuchi Y, Hagiwara Y, Matsuyama Y. Marginal structural Cox models in nested case-control studies with time-varying treatments. 42nd Conference of the International Society for Clinical Biostatistics. Online. Jul 2021.
  2. Takeuchi Y. Kumamaru H, Hagiwara Y, Matsui H, Yasunaga H, Miyata H, Matsuyama Y, Risk of Sodium-Glucose Cotransporter-2 Inhibitor on the Incidence of Urinary Tract Infection among Diabetic Patients in Japan: A Nationwide Cohort Study (poster presentation). ICPE All Access. Online. Sep 2020.
  3. Hagiwara Y, Kawahara T, Shiroiwa T. What is a valid mapping algorithm in cost-utility analyses? An answer from a missing data perspective. International Society for Pharmacoeconomics and Outcome Research Europe 2019. Copenhergen, Denmark. November 2019. PNS323.
  4. Takeuchi Y, Ogawa M, Hagiwara Y, Matsuyama Y. Multiple imputation for survival analysis with missing covariates using non-parametric estimation. 12th Asian Conference on Pharmacoepidemiology and 25th Japanese Conference on Pharmacoepidemiology joint meeting. Kyoto. Oct 2019.
  5. Kobayashi K, Taira N, Sawaki M, Sagawa N, Baba S, Saito T, Kawahara T, Hagiwara Y, Uemura Y, Shimozuma K, Ohashi Y, Mukai H. Patient-reported outcomes with trastuzumab monotherapy versus trastuzumab plus standard chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT): A randomized, open-label, phase 3 clinical trial. San Antonio Breast Cancer Symposium 2018. San Antonio, the United States, December 2018.
  6. Takahashi M, Sawaki M, Hagiwara Y, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Saito T, Baba S, Kobayashi K, Mukai H, Taira N. Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, phase 3 clinical trial (RESPECT trial). San Antonio Breast Cancer Symposium 2018. San Antonio, the United States, December 2018.
  7. Hagiwara Y, Taira N, Saito T, Baba S, Kobayashi K, Kawahara T, Shiroiwa T, Fukuda T, Shimozuma K, Uemura Y, Mukai H, Ohashi Y, Sawaki M. The EQ-5D index of elderly patients with HER-2 positive breast cancer: results from the randomized N-SAS BC 07 trial for adjuvant trastuzumab with and without chemotherapy. International Society for Pharmacoeconomics and Outcome Research Asia Pacific 2018 Conference. Tokyo, Japan. September 2018. PCN65.
  8. Hagiwara Y, Shinozaki T, Matsuyama Y. G-estimation of structural nested restricted mean time lost models to estimate effect of time-varying treatment on survival outcome. 29th International Biometric Conference. Barcelona, Spain. July 2018. CS41.1.
  9. Yoshino T, Yamanaka T, Denda T,Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Shitara K. REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: quality of life analysis. European Society for Medical Oncology World Congress on Gastrointestinal Cancer 2018. Barcelona, Spain. June 2018.
  10. Tsuji Y, Shitara K, Yamanaka T, Denda T, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T. REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated With fluoropyrimidine, oxaliplatin, and irinotecan— biomarker analysis. American Society of Clinical Oncology Annual Meeting 2018, Chicago, US, June 3, 2018. Abstract 3510.
  11. Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Kawahara T, Ohsumi S, Hozumi Y, Sagara Y, Ohashi Y, Mukai H. Cost-effectiveness of first-line S-1 therapy for metastatic breast cancer patients compared with taxanes: an analysis based on the randomized phase III SELECT BC trial. International Society for Pharmacoeconomics and Outcome Research 19th Annual European Congress, Vienna, Austria, November 2. Abstract PCN161.
  12. Hagiwara Y, Shimozuma K, Shiroiwa T, Kawahara T, Uemura Y, Watanabe T, Taira N, Fukuda T, Ohashi Y, Mukai H. Impacts of adverse events on health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer : results from randomized phase III SELECT BC study. International Society for Pharmacoeconomics and Outcome Research 19th Annual European Congress, Vienna, Austria, November 2. Abstract PCN204.
  13. Kawahara T, Shimozuma K, Shiroiwa T, Hagiwara Y, Uemura Y, Watanabe T, Fukuda T, Ohashi Y, Mukai H. Responder analyses of patient-reported outcomes for evaluating the clinical significance of first-line S-1 over taxane therapy among patients with metastatic breast cancer: the open-label randomized phase III SELECT BC trial. International Society for Quality of Life Research 23rd Annual Conference, Copenhagen, Denmark, October 21. Abstract 2029.
  14. Sho M, Shimizu A, Yanagimoto H, Nakamori S, Okusaka T, Ishii H, Kitano M, Sugimori K, Maguchi H, Ohkawa S, Imaoka H, Hashimoto D, Ueda K, Nebiki H, Nagakawa T, Isayama H, Hagiwara Y, Ohashi Y, Shirasaka T, Yamaue H. Multicenter randomized phase II study comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with locally advanced and metastatic pancreatic cancer: PAN-01 study. American Society for Clinical Oncology annual meeting 2016, Chicago, US, June, 2016. J Clin Oncol. 2016; 34(suppl; abstr 4107).
  15. Hagiwara Y, Shinozaki T, Matsuyama Y. Estimation of modified effectiveness in randomized trials with subsequent treatments using dynamic marginal structural models. UK Causal Inference Meeting 4th annual meeting, London, England, April 13, 2016. P18.
  16. Fukuda T, Shiroiwa T, Simozuma K, Mori M, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Hagiwara Y, Ohashi Y, Mukai H. Long-term EQ-5D score for patients with metastatic breast cancer; comparison of first-line oral S-1 and Taxane therapies in the randomized SLECT trial. International Society for Pharmacoeconomics and Outcome Research 18th Annual European Congress, Milan, Italy, November 9, 2015. Abstract PCN210.

Symposium

  1. Hagiwara Y. Estimation of modified effectiveness in confirmatory cancer clinical trials using dynamic marginal structural models. PeSeTo International Symposium on Public Health 2016, Tokyo, Japan, March 15, 2016.

TOP